Hobbs Group Advisors LLC Sells 418 Shares of Novo Nordisk A/S (NYSE:NVO)

Hobbs Group Advisors LLC decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 3.2% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 12,494 shares of the company’s stock after selling 418 shares during the period. Hobbs Group Advisors LLC’s holdings in Novo Nordisk A/S were worth $1,488,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in NVO. Envestnet Asset Management Inc. increased its position in shares of Novo Nordisk A/S by 1.4% in the 2nd quarter. Envestnet Asset Management Inc. now owns 4,254,180 shares of the company’s stock valued at $607,242,000 after buying an additional 58,935 shares in the last quarter. Raymond James & Associates increased its position in shares of Novo Nordisk A/S by 1.0% in the 3rd quarter. Raymond James & Associates now owns 3,526,821 shares of the company’s stock valued at $419,939,000 after buying an additional 36,223 shares in the last quarter. Natixis Advisors LLC increased its position in shares of Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after buying an additional 80,070 shares in the last quarter. International Assets Investment Management LLC increased its position in shares of Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after buying an additional 1,796,635 shares in the last quarter. Finally, DSM Capital Partners LLC increased its position in shares of Novo Nordisk A/S by 257,816.0% in the 2nd quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock valued at $227,516,000 after buying an additional 1,593,303 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on NVO. Cantor Fitzgerald restated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets lowered their price objective on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. BNP Paribas upgraded shares of Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. One analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Buy” and an average target price of $150.40.

Novo Nordisk A/S Price Performance

Shares of NYSE NVO opened at $109.19 on Wednesday. The firm has a market cap of $489.99 billion, a PE ratio of 35.34, a PEG ratio of 1.41 and a beta of 0.40. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a 1-year low of $94.73 and a 1-year high of $148.15. The company has a fifty day moving average price of $111.15 and a 200 day moving average price of $126.90.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.